Syndax Pharmaceuticals (NASDAQ:SNDX) Director Dennis Podlesak Sells 8,000 Shares of Company Stock

Posted by George Bondi on Oct 31st, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) Director Dennis Podlesak sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the sale, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $13.65 on Friday. The business has a 50 day moving average of $17.18 and a 200-day moving average of $20.25. Syndax Pharmaceuticals, Inc. has a 1 year low of $12.80 and a 1 year high of $25.59. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. The company has a market capitalization of $1.21 billion, a P/E ratio of -5.44 and a beta of 0.42.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%. The business had revenue of $72.79 million for the quarter, compared to analyst estimates of $79.36 million. During the same quarter in the prior year, the business earned ($0.83) earnings per share. The firm’s quarterly revenue was up 91.8% on a year-over-year basis. On average, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Weiss Ratings lowered shares of Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 19th. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, October 13th. UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Finally, JPMorgan Chase & Co. cut their target price on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.80.

Read Our Latest Stock Report on Syndax Pharmaceuticals

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP bought a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter valued at about $26,000. Sterling Capital Management LLC grew its stake in Syndax Pharmaceuticals by 846.6% during the third quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock worth $56,000 after purchasing an additional 2,650 shares during the period. Nykredit A S acquired a new stake in Syndax Pharmaceuticals during the second quarter worth approximately $72,000. Integrated Wealth Concepts LLC bought a new stake in Syndax Pharmaceuticals in the second quarter worth approximately $73,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Syndax Pharmaceuticals in the third quarter worth approximately $86,000.

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.